Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- University of Pittsburgh
- Study ID
- NCT07760779
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Insomnia
- Nocturia
Eligibility Criteria
- Sex
- FEMALE
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Brief behavioral treatment of insomnia — BEHAVIORALBBTI: will entail a 45- to 60-minute individual intervention session with instructions regarding sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. This education provides the rationale for the 4 main interventions of BBTI: 1. reduce time in bed; 2. get up at the same time every day, regardless of sleep duration; 3. do not go to bed unless sleepy; and 4. do not stay in bed unless asleep
- MI — BEHAVIORALParticipants in the MI group will be trained to engage in a brief mindfulness method involving body scan with acceptance language training.
- Control — BEHAVIORALThe control condition is intended to emulate the behavioral treatment information generally available to patients.
- BBTI+MI — BEHAVIORALParticipants in this arm will receive BBTI as well as MI training.
Study Details
The goal of this clinical trial is to examine and compare the effect of behavioral sleep treatment: BBTI (brief behavioral treatment of insomnia) and brief mindfulness (MI), independently and combined vs control on frequency of nighttime awakenings to void (nocturia) and on nighttime urine production in older women over the age 65 years with nocturia. To study the effect of these treatments, participants will be randomly assigned to one of the following groups 1) BBTI alone, 2) MI alone, 3) BBTI+MI, or 4) control: sleep information only without any structured sleep or mindfulness therapy. The study aims to examine the effect of these therapies at end-of-treatment (week 4), as well sustained effects at 3- and 6-months. The main questions the study aims to answer are: 1. do these treatments reduce the frequency of nighttime awakenings to void 2. do these treatments reduce the volume of nighttime urine production 3. do these treatments improve sleep quality Frequency of nocturia and sleep quality will be assessed via questionnaires and nighttime urine volume using bladder-sleep diaries which is 3-day record participants will complete at home documenting every time they go to the bathroom and volume they voided. In addition, sleep and sleep interruptions will also be assessed using an FDA-cleared home sleep testing device called Zmachine®.
Key Dates
- First listed
- Aug 12, 2026
- Start date
- Sep 15, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 30, 2028
- Completion
- Apr 30, 2029
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Other: Control
- Experimental: BBTIBrief behavioral treatment of insomnia
- Experimental: MIBrief mindfulness
- Experimental: BBTI+MIBrief behavioral treatment of insomnia and brief mindfulness
Primary Outcome Measure
Nocturia [ Time Frame: 4 weeks, 3- and 6-months post-intervention ]
Central Contacts
- Shachi Tyagi, MD, MS14126471274
- Becky D Clarkson, PhD4126471270
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 |
Find similar trials in Pittsburgh, PA
Related Studies
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Little Rock, Arkansas
- Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in InsomniaEARLY_PHASE1 · Recruiting · Milton S. Hershey Medical Center · Denver, Colorado
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)PHASE3 · Recruiting · Merck Sharp & Dohme LLC · New Haven, Connecticut
- APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in WomenRecruiting · Medstar Health Research Institute · Birmingham, Alabama